Published: 4 June 2020


Recent approvals: new active ingredients or new indications

Prescriber Update 41(2): 34
June 2020

For the period 16 January 2020 to 15 April 2020.

Recent approvals of medicines with new active ingredients

Trade name (Active ingredient) Dose form and strength(s) Therapeutic area
Aimovig (erenumab) Solution for injection
70 mg/mL
70 mg/mL pen
Brintellix (vortioxetine) Tablet
5 mg
10 mg
15 mg
20 mg
Major depressive disorder
Fasenra (benralizumab) Solution for injection
30 mg/mL
Eosinophilic asthma
Lenvima (lenvatinib) Capsule
4 mg
10 mg
Thyroid cancer
Renal cell carcinoma
Hepatocellular carcinoma
Nitisinone DiPharma (nitisinone) Capsule
2 mg
5 mg
10 mg
Hereditary tyrosinemia type 1 (HT-1)
Oncaspar (pegaspargase) Solution for injection
3750 U/5mL
Acute lymphoblastic leukaemia

Approved medicines with new indications

Keytruda (pembrolizumab) Powder for infusion
50 mg
Concentrate for infusion
25 mg/mL
Renal cell carcinoma
Praluent (alirocumab) Solution for injection
75 mg/mL
150 mg/mL
Prevention of cardiovascular events
Xgeva (denosumab) Solution for injection
70 mg/mL
Multiple myeloma
Giant cell tumour of bone
Hypercalcaemia of malignancy

See the Medsafe website for more information about these medicines. Data sheets of currently marketed medicines are also available.

Hide menus
Show menus
0 1 2 4 5 6 7 9 [ /